NuCana to Present at the Jefferies 2019 London Healthcare Conference
November 14, 2019 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update
November 13, 2019 16:01 ET
|
NuCana plc
Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal...
NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 29, 2019 07:00 ET
|
NuCana plc
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE...
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
October 25, 2019 07:00 ET
|
NuCana plc
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three...
NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
August 29, 2019 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana to Participate in Citi’s 14th Annual Biotech Conference
August 27, 2019 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host...
NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update
August 21, 2019 16:01 ET
|
NuCana plc
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, Aug. 21, 2019 (GLOBE NEWSWIRE)...
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis
August 20, 2019 08:00 ET
|
NuCana plc
Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to Determine Path Forward Encouraging Survival Trends Observed in Patient Sub-Groups...
NuCana Announces First Patients Dosed in Phase I Study of NUC-7738
July 17, 2019 07:00 ET
|
NuCana plc
NUC-7738 is NuCana’s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc...
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer
June 12, 2019 19:24 ET
|
NuCana plc
EDINBURGH, United Kingdom, June 12, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the...